BACKGROUND: The Centers for Disease Control and Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea to ensure effective treatment and slow emergence of antimicrobial resistance. Since 2013, the prevalence of reduced azithromycin susceptibility increased in the United States; however, these strains were highly susceptible to cephalosporins. We identified a cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance, several of which also demonstrated decreased ceftriaxone susceptibility. METHODS: Eight N. gonorrhoeae isolates collected from 7 patients on Oahu, Hawaii, seen 21 April 2016 through 10 May 2016 underwent routine Etest antimicrobial susceptibility testing by the Hawaii Department of Health. All demonstrated elevated azithromycin minimum inhibitory concentrations (MICs) >256 μg/mL and elevated ceftriaxone MICs (≥0.125 μg/mL). Isolates were sent to the University of Washington and CDC for confirmatory agar dilution testing; sequence data were sent to CDC for analysis. All patients were interviewed and treated, and when possible, partners were interviewed, tested, and treated. RESULTS: All isolates had azithromycin MICs >16 µg/mL and 5 had ceftriaxone MICs = 0.125 µg/mL by agar dilution. All isolates were β-lactamase positive and were resistant to penicillin, tetracycline, and ciprofloxacin. Genomic analysis revealed genetic relatedness. No patients reported recent travel or antibiotic use, and no male patients reported male sex partners. All patients were successfully treated. CONCLUSIONS: This cluster of genetically related gonococcal isolates with decreased ceftriaxone susceptibility and high-level azithromycin resistance may bring the threat of treatment failure in the United States with the current recommended dual therapy one step closer.
BACKGROUND: The Centers for Disease Control and Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea to ensure effective treatment and slow emergence of antimicrobial resistance. Since 2013, the prevalence of reduced azithromycin susceptibility increased in the United States; however, these strains were highly susceptible to cephalosporins. We identified a cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance, several of which also demonstrated decreased ceftriaxone susceptibility. METHODS: Eight N. gonorrhoeae isolates collected from 7 patients on Oahu, Hawaii, seen 21 April 2016 through 10 May 2016 underwent routine Etest antimicrobial susceptibility testing by the Hawaii Department of Health. All demonstrated elevated azithromycin minimum inhibitory concentrations (MICs) >256 μg/mL and elevated ceftriaxone MICs (≥0.125 μg/mL). Isolates were sent to the University of Washington and CDC for confirmatory agar dilution testing; sequence data were sent to CDC for analysis. All patients were interviewed and treated, and when possible, partners were interviewed, tested, and treated. RESULTS: All isolates had azithromycin MICs >16 µg/mL and 5 had ceftriaxone MICs = 0.125 µg/mL by agar dilution. All isolates were β-lactamase positive and were resistant to penicillin, tetracycline, and ciprofloxacin. Genomic analysis revealed genetic relatedness. No patients reported recent travel or antibiotic use, and no male patients reported male sex partners. All patients were successfully treated. CONCLUSIONS: This cluster of genetically related gonococcal isolates with decreased ceftriaxone susceptibility and high-level azithromycin resistance may bring the threat of treatment failure in the United States with the current recommended dual therapy one step closer.
Authors: Susan A Wang; Maria Veneranda C Lee; Norman O'Connor; Christopher J Iverson; Roy G Ohye; Peter M Whiticar; Judith A Hale; David L Trees; Joan S Knapp; Paul V Effler; Hillard S Weinstock Journal: Clin Infect Dis Date: 2003-08-28 Impact factor: 9.079
Authors: Severin Gose; Carol J Kong; Yer Lee; Michael C Samuel; Heidi M Bauer; Paula Dixon; Olusegun O Soge; John Lei; Mark Pandori Journal: J Microbiol Methods Date: 2013-12 Impact factor: 2.363
Authors: Alan R Katz; Alan Y Komeya; Olusegun O Soge; Mandy I Kiaha; Maria Veneranda C Lee; Glenn M Wasserman; Eloisa V Maningas; A Christian Whelen; Robert D Kirkcaldy; Steven J Shapiro; Gail A Bolan; King K Holmes Journal: Clin Infect Dis Date: 2011-12-19 Impact factor: 9.079
Authors: Sarah Kidd; Maria V C Lee; Eloisa Maningas; Alan Komeya; Gail Kunimoto; Norman O'Connor; Alan R Katz; Glenn M Wasserman; Robert D Kirkcaldy; A Christian Whelen Journal: Sex Transm Dis Date: 2013-09 Impact factor: 2.830
Authors: Charlotte A Gaydos; Michele-Corinne Ako; Mitra Lewis; Yu-Hsiang Hsieh; Richard E Rothman; Andrea F Dugas Journal: Ann Emerg Med Date: 2018-11-02 Impact factor: 5.721
Authors: Sanjay Ram; Sunita Gulati; Lisa A Lewis; Srinjoy Chakraborti; Bo Zheng; Rosane B DeOliveira; George W Reed; Andrew D Cox; Jianjun Li; Frank St Michael; Jacek Stupak; Xiao-Hong Su; Sudeshna Saha; Corinna S Landig; Ajit Varki; Peter A Rice Journal: Infect Immun Date: 2018-07-23 Impact factor: 3.441
Authors: Jutamas Shaughnessy; Lisa A Lewis; Bo Zheng; Caleb Carr; Isaac Bass; Sunita Gulati; Rosane B DeOliveira; Severin Gose; George W Reed; Marina Botto; Peter A Rice; Sanjay Ram Journal: J Immunol Date: 2018-09-28 Impact factor: 5.422
Authors: Jose A Bazan; Mysheika Williams Roberts; Olusegun O Soge; Elizabeth A Torrone; Amanda Dennison; Melissa Ervin; Sopheay Hun; Karen S Fields; Abigail N Turner Journal: Sex Transm Dis Date: 2018-02 Impact factor: 2.830
Authors: Cau D Pham; Evelyn Nash; Hsi Liu; Matthew W Schmerer; Samera Sharpe; Grace Woods; Brad Roland; Karen Schlanger; Sancta B St Cyr; Jonathan Carlson; Kevin Sellers; Aaron Olsen; Ruth Sanon; Henrietta Hardin; Olusegun O Soge; Brian H Raphael; Ellen N Kersh Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191